Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year After 4 initiating doses in the first 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results